To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Mucosal adjuvants and ant… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA

Journal article
Authors Jan Holmgren
Jenni Adamsson
F. Anjuere
J. Clemens
C. Czerkinsky
Kristina Eriksson
Carl-Fredrik Flach
Annie George-Chandy
Ali M Harandi
Michael Lebens
T. Lehner
Marianne Lindblad
Erik Nygren
Sukanya Raghavan
Joaquin Sanchez
M. Stanford
Jia-Bin Sun
Ann-Mari Svennerholm
Sara Tengvall
Published in Immunol Lett
Volume 97
Issue 2
Pages 181-8
Publication year 2005
Published at Institute of Medical Microbiology/Immunology
Pages 181-8
Language en
Keywords *Adjuvants, Immunologic, Animals, Behcet Syndrome/immunology/prevention & control, Cholera Toxin/chemistry/*immunology, CpG Islands/genetics/*immunology, Humans, Immunity, Mucosal/immunology, Vaccines/*immunology
Subject categories Medical and Health Sciences


Mucosal immunisation may be used both to protect the mucosal surfaces against infections and as a means for immunological treatment of peripheral immunopathological disorders through the induction of systemic antigen-specific tolerance ('oral tolerance'). The development of mucosal vaccines, whether for prevention of infectious diseases or for oral tolerance immunotherapy, requires efficient antigen delivery and adjuvant systems that can help to present the appropriate vaccine or immunotherapy antigens to the mucosal immune system. The most potent (but also toxic) mucosal adjuvants are cholera toxin (CT) and the closely related Escherichia coli heat-labile enterotoxin (LT), and much effort and significant progress have been made recently to generate toxicologically acceptable derivatives of these toxins with retained adjuvant activity. Among these are the non-toxic, recombinantly produced cholera toxin B-subunit (CTB). CTB is a specific protective antigen component of a widely registered oral cholera vaccine as well as a promising vector for either giving rise to mucosal anti-infective immunity or for inducing peripheral anti-inflammatory tolerance to chemically or genetically linked foreign antigens administered mucosally. CT and CTB have also recently been used as combined vectors and adjuvants for markedly promoting ex vivo dendritic cell (DC) vaccination with different antigens and also steering the immune response to the in vivo-reinfused DCs towards either broad Th1 + Th2 + CTL immunity (CT) or Th2 or tolerance (CTB). Another type of mucosal adjuvants is represented by bacterial DNA or synthetic oligodeoxynucleotides containing CpG-motifs, which especially when linked to CTB have been found to effectively stimulate both innate and adaptive mucosal immune responses. The properties and clinical potential of these different classes of adjuvants are being discussed.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?